Corrected: Syndax stops PhI/II leukemia study early after menin inhibitor shows efficacy in challenging mutation

Ayisha Sharma

News Reporter

Syndax Pharmaceuticals’ menin inhibitor revumenib has met the primary endpoint in niche patient groups in a registrational leukemia trial, prompting an early end to the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Corrected: Syndax stops PhI/II leukemia study early after menin inhibitor shows efficacy in challenging mutation

Ayisha Sharma

News Reporter

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

Sanofi's BTK inhibitor again slows MS progression, but liver enzymes continue to be tricky

Lexicon's president to step down as decision date looms; Sarepta welcomes Lilly, GSK vet to board

Gilead's Kite uncouples from Fosun in China as Yescarta faces coverage obstacles

Aligos’ trial for oral MASH treatment succeeds, but placebo group shows odd trend

FDA inspectors discover trucks carrying torn-up records leaving Indian generics factory

Breaking down silos with a new quantitative approach to drug development

Cor­rect­ed: Syn­dax stops PhI/II leukemia study ear­ly af­ter menin in­hibitor shows ef­fi­ca­cy in chal­leng­ing mu­ta­tion

News Reporter

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Corrected: Syndax stops PhI/II leukemia study early after menin inhibitor shows efficacy in challenging mutation